IP Library Granted Patent US 7,317,001
Granted Patent B2
US 7,317,001 · App. 10/454,998 · Granted Jan 8, 2008

Use of ramoplanin to treat diseases associated with the use of antibiotics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,317,001
App. No.
10/454,998
Granted
Jan 8, 2008
Kind
B2
Abstract

The invention features a method of treating or preventing a disease associated with the use of antibiotics in a patient in need thereof by administering to the patient ramoplanin in an amount and for a duration effective to treat said disease. The disease may be caused, for example, by the presence of a bacterium such as enterotoxin producing strains of C. difficile, C. perfringens , or S. aureus.

Claims (8)

1. A method of treating a patient with a Clostridium difficile -associated condition, said method comprising administering to said patient ramoplanin in an amount and for a duration effective to treat said condition, wherein said method is effective for reducing the population of Clostridium difficile and Clostridium difficile spores.

2. The method of claim 1 , wherein said Clostridium difficile is resistant to metronidazole and/or vancomycin.

3. The method of claim 1 , wherein said Clostridium difficile -associated condition is selected from the group consisting of antibiotic-associated diarrhea, colitis, and pseudomembranous colitis.

4. The method of claim 1 , wherein said ramoplanin is administered in an amount between 50 mg and 1 g.

5. The method of claim 4 , wherein said ramoplanin is administered in an amount between 200 and 400 mg once or twice daily.

6. The method of claim 1 , wherein said ramoplanin is administered one to four times daily for three to fifteen days.

7. The method of claim 1 , wherein said ramoplanin is administered orally.

8. The method of claim 1 , further comprising administering to said patient vancomycin, bacitracin, or metronidazole.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2018
From: NANOTHERAPEUTICS INC
To: NANOSHIFT, LLC
Reel/Frame 046669/0740 →
RELEASE OF SECURITY INTEREST Recorded May 19, 2016
From: WHITE OAK GLOBAL ADVISORS, LLC AS AGENT
To: NANOTHERAPEUTICS, INC.
Reel/Frame 038651/0947 →
SECURITY INTEREST Recorded Mar 20, 2015
From: NANOTHERAPEUTICS, INC.
To: WHITE OAK GLOBAL ADVISORS, LLC
Reel/Frame 035236/0932 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2009
From: OSCIENT PHARMACEUTICALS CORPORATION
To: NANOTHERAPEUTICS, INC.
Reel/Frame 023668/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2007
From: VICURON PHARMACEUTICALS, INC.
To: OSCIENT PHARMACEUTICALS CORPORATION
Reel/Frame 018820/0985 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2006
From: MOSCONI, GIORGIO
To: VICURON PHARMACEUTICALS, INC.
Reel/Frame 018578/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2006
From: VICURON PHARMACEUTICALS, INC.
To: OSCIENT PHARMACEUTICALS CORPORATION
Reel/Frame 017335/0215 →
CHANGE OF NAME Recorded Mar 13, 2006
From: GENOME THERAPEUTICS CORP.
To: OSCIENT PHARMACEUTICALS CORPORATION
Reel/Frame 017335/0220 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2003
From: LEACH, TIMOTHY S.; LABAUDINIERE, RICHARD F.; RAUSCHER, STEVEN M.
To: GENOME THERAPEUTICS CORPORATION
Reel/Frame 014207/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2003
From: JABES, DANIELA
To: VICURON PHARMACEUTICALS, INC.
Reel/Frame 014207/0672 →